CPVI Alone Versus. CPVI Plus Electrophysiological Substrate Ablation in the LA During SR for the Treatment of Non-PAF

NCT03448562 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2020-02-11

No results posted yet for this study

Summary

The primary objective of this investigation is to compare the efficacy of two different AF ablation strategies in patients with non-paroxysmal AF: CPVI plus electrophysiologic substrate ablation in the left atrium during sinus rhythm (STABLE-SR) and CPVI alone.

Conditions

Interventions

PROCEDURE

CPVI

ablate around the pulmonary vein orifice

PROCEDURE

STABLE-SR

homogenization of the low voltage zones and elimination of the complex electrograms from the transitional zones during sinus rhythm

Sponsors & Collaborators

  • First Affiliated Hospital of Zhejiang University

    collaborator OTHER
  • Fudan University

    collaborator OTHER
  • First Affiliated Hospital of Wannan Medical College

    collaborator OTHER
  • The Second Hospital of Hebei Medical University

    collaborator OTHER
  • General Hospital of Shenyang Military Region

    collaborator OTHER
  • First Affiliated Hospital, Sun Yat-Sen University

    collaborator OTHER
  • Guangdong Provincial People's Hospital

    collaborator OTHER
  • Zhongda Hospital

    collaborator OTHER
  • University of Pennsylvania

    collaborator OTHER
  • Southlake Regional Health Centre

    collaborator OTHER
  • German Heart Institute

    collaborator OTHER
  • Asklepios Kliniken Hamburg GmbH

    collaborator OTHER
  • National University Hospital, Singapore

    collaborator OTHER
  • Royal Brompton & Harefield NHS Foundation Trust

    collaborator OTHER
  • National Heart Centre Singapore

    collaborator OTHER
  • Semmelweis University Heart and Vascular Center

    collaborator OTHER
  • University of Minnesota

    collaborator OTHER
  • The First Affiliated Hospital with Nanjing Medical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-01
Primary Completion
2020-09-30
Completion
2020-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03448562 on ClinicalTrials.gov